Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation

J. Chalmers, M. Cooper, E. Ferrannini, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, L. Liu, S. MacMahon, G. Mancia, M. Marre, D. Matthews, C. Mogensen, B. Neal, C. Yu Pan, N. Poulter, A. Rodgers, B. Williams, M. Woodward, R. CollinsP. Sandercock, P. Sleight, R. Holman, G. Fulcher, C. Pollock, D. Celermajer, J. Watson, B. Harrisberg, R. Currie, S. Girgis, K. Jayne, H. Monaghan, A. Patel, A. Richens, B. Gray, A. Milne, A. Adderkin, A. Bak, S. Flett, D. De Guise, E. Jetses, J. Reid, R. Stolk, W. Wang, F. Williams, X. Zou

Research output: Contribution to journalArticle

Abstract

Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.

Original languageEnglish (US)
Pages (from-to)1118-1120
Number of pages3
JournalDiabetologia
Volume44
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

perindopril drug combination indapamide
Gliclazide
Vascular Diseases
Indapamide
Perindopril
Blood Pressure
Australasia
Glucose
Eye Diseases
Diabetic Nephropathies
Therapeutics
North America
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Type 2 Diabetes Mellitus
Blood Glucose
Randomized Controlled Trials
Stroke
Myocardial Infarction
Placebos

Keywords

  • Blood glucose
  • Blood pressure
  • Cardiovascular disease
  • Controlled clinical trial
  • Diabetes mellitus
  • Diabetic nephropathy
  • Diabetic retinopathy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Chalmers, J., Cooper, M., Ferrannini, E., Glasziou, P., Grobbee, D., Hamet, P., ... Zou, X. (2001). Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation. Diabetologia, 44(9), 1118-1120. https://doi.org/10.1007/s001250100612

Study rationale and design of ADVANCE : Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation. / Chalmers, J.; Cooper, M.; Ferrannini, E.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Liu, L.; MacMahon, S.; Mancia, G.; Marre, M.; Matthews, D.; Mogensen, C.; Neal, B.; Yu Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Woodward, M.; Collins, R.; Sandercock, P.; Sleight, P.; Holman, R.; Fulcher, G.; Pollock, C.; Celermajer, D.; Watson, J.; Harrisberg, B.; Currie, R.; Girgis, S.; Jayne, K.; Monaghan, H.; Patel, A.; Richens, A.; Gray, B.; Milne, A.; Adderkin, A.; Bak, A.; Flett, S.; De Guise, D.; Jetses, E.; Reid, J.; Stolk, R.; Wang, W.; Williams, F.; Zou, X.

In: Diabetologia, Vol. 44, No. 9, 2001, p. 1118-1120.

Research output: Contribution to journalArticle

Chalmers, J, Cooper, M, Ferrannini, E, Glasziou, P, Grobbee, D, Hamet, P, Harrap, S, Liu, L, MacMahon, S, Mancia, G, Marre, M, Matthews, D, Mogensen, C, Neal, B, Yu Pan, C, Poulter, N, Rodgers, A, Williams, B, Woodward, M, Collins, R, Sandercock, P, Sleight, P, Holman, R, Fulcher, G, Pollock, C, Celermajer, D, Watson, J, Harrisberg, B, Currie, R, Girgis, S, Jayne, K, Monaghan, H, Patel, A, Richens, A, Gray, B, Milne, A, Adderkin, A, Bak, A, Flett, S, De Guise, D, Jetses, E, Reid, J, Stolk, R, Wang, W, Williams, F & Zou, X 2001, 'Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation', Diabetologia, vol. 44, no. 9, pp. 1118-1120. https://doi.org/10.1007/s001250100612
Chalmers, J. ; Cooper, M. ; Ferrannini, E. ; Glasziou, P. ; Grobbee, D. ; Hamet, P. ; Harrap, S. ; Liu, L. ; MacMahon, S. ; Mancia, G. ; Marre, M. ; Matthews, D. ; Mogensen, C. ; Neal, B. ; Yu Pan, C. ; Poulter, N. ; Rodgers, A. ; Williams, B. ; Woodward, M. ; Collins, R. ; Sandercock, P. ; Sleight, P. ; Holman, R. ; Fulcher, G. ; Pollock, C. ; Celermajer, D. ; Watson, J. ; Harrisberg, B. ; Currie, R. ; Girgis, S. ; Jayne, K. ; Monaghan, H. ; Patel, A. ; Richens, A. ; Gray, B. ; Milne, A. ; Adderkin, A. ; Bak, A. ; Flett, S. ; De Guise, D. ; Jetses, E. ; Reid, J. ; Stolk, R. ; Wang, W. ; Williams, F. ; Zou, X. / Study rationale and design of ADVANCE : Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation. In: Diabetologia. 2001 ; Vol. 44, No. 9. pp. 1118-1120.
@article{335cb6205df44b09a33eae0a8044ca87,
title = "Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation",
abstract = "Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.",
keywords = "Blood glucose, Blood pressure, Cardiovascular disease, Controlled clinical trial, Diabetes mellitus, Diabetic nephropathy, Diabetic retinopathy",
author = "J. Chalmers and M. Cooper and E. Ferrannini and P. Glasziou and D. Grobbee and P. Hamet and S. Harrap and L. Liu and S. MacMahon and G. Mancia and M. Marre and D. Matthews and C. Mogensen and B. Neal and {Yu Pan}, C. and N. Poulter and A. Rodgers and B. Williams and M. Woodward and R. Collins and P. Sandercock and P. Sleight and R. Holman and G. Fulcher and C. Pollock and D. Celermajer and J. Watson and B. Harrisberg and R. Currie and S. Girgis and K. Jayne and H. Monaghan and A. Patel and A. Richens and B. Gray and A. Milne and A. Adderkin and A. Bak and S. Flett and {De Guise}, D. and E. Jetses and J. Reid and R. Stolk and W. Wang and F. Williams and X. Zou",
year = "2001",
doi = "10.1007/s001250100612",
language = "English (US)",
volume = "44",
pages = "1118--1120",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Study rationale and design of ADVANCE

T2 - Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation

AU - Chalmers, J.

AU - Cooper, M.

AU - Ferrannini, E.

AU - Glasziou, P.

AU - Grobbee, D.

AU - Hamet, P.

AU - Harrap, S.

AU - Liu, L.

AU - MacMahon, S.

AU - Mancia, G.

AU - Marre, M.

AU - Matthews, D.

AU - Mogensen, C.

AU - Neal, B.

AU - Yu Pan, C.

AU - Poulter, N.

AU - Rodgers, A.

AU - Williams, B.

AU - Woodward, M.

AU - Collins, R.

AU - Sandercock, P.

AU - Sleight, P.

AU - Holman, R.

AU - Fulcher, G.

AU - Pollock, C.

AU - Celermajer, D.

AU - Watson, J.

AU - Harrisberg, B.

AU - Currie, R.

AU - Girgis, S.

AU - Jayne, K.

AU - Monaghan, H.

AU - Patel, A.

AU - Richens, A.

AU - Gray, B.

AU - Milne, A.

AU - Adderkin, A.

AU - Bak, A.

AU - Flett, S.

AU - De Guise, D.

AU - Jetses, E.

AU - Reid, J.

AU - Stolk, R.

AU - Wang, W.

AU - Williams, F.

AU - Zou, X.

PY - 2001

Y1 - 2001

N2 - Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.

AB - Aims/hypothesis. Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce microvascular disease but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that lowering blood pressure with an ACE inhibitor-diuretic combination and intensively controlling gylcaemia with a sulphonylurea-based regimen in high-risk patients with Type II diabetes (both hypertensive and non-hypertensive) reduces the incidence of macrovascular and microvascular disease. Methods. The study is a 2 × 2 factorial randomised controlled trial that will include 10000 adults with Type II diabetes at high risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible patients are randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. The scheduled average duration of treatment and follow-up is 4.5 years. The study will be conducted in approximately 200 centres in Australasia, Asia, Europe and North America. Conclusion/interpretation. ADVANCE is designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.

KW - Blood glucose

KW - Blood pressure

KW - Cardiovascular disease

KW - Controlled clinical trial

KW - Diabetes mellitus

KW - Diabetic nephropathy

KW - Diabetic retinopathy

UR - http://www.scopus.com/inward/record.url?scp=17944382481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944382481&partnerID=8YFLogxK

U2 - 10.1007/s001250100612

DO - 10.1007/s001250100612

M3 - Article

C2 - 11596665

AN - SCOPUS:17944382481

VL - 44

SP - 1118

EP - 1120

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -